Year-over-year, this metric grew by 38.4%, from $550.90M to $762.30M. Over 2 years (FY 2021 to FY 2025), Free cash flow shows a downward trend with a -30.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $744.30M | $1.23B | $300.90M | $1.05B | $555.70M | $713.20M | $0.00 | $451.00M | $323.10M | $376.40M | $534.80M | $574.40M | $547.90M | $550.90M | $467.70M | $546.00M | $0.00 | $762.30M |
| QoQ Change | — | +65.5% | -75.6% | +248.5% | -47.0% | +28.3% | -100.0% | — | -28.4% | +16.5% | +42.1% | +7.4% | -4.6% | +0.5% | -15.1% | +16.7% | -100.0% | — |
| YoY Change | — | — | — | — | -25.3% | -42.1% | -100.0% | -57.0% | -41.9% | -47.2% | +18.6% | +77.8% | +45.6% | +3.0% | -18.6% | -0.3% | — | +38.4% |